Compare Abeona Therapeutics Inc (ABEO) vs Rivian Automotive, Inc. (RIVN) Price & Performance

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Rivian (RIVN) trades at $16.39, up 2.44% today, showing bullish technical signals with recent price momentum. The company continues to narrow losses, with Q2 2026 EPS beating expectations at -$0.47 versus -$0.66 expected. Revenue growth is steady, reaching $5.39B in 2025, while cash burn remains a key focus as the R2 vehicle ramp-up progresses.

Outlook is cautiously optimistic with analyst consensus price target of $18.70 offering potential upside. Key opportunities include R2 demand and margin improvements, but risks from high cash burn and competitive pressures persist. Execution on profitability targets will be critical for sustained stock appreciation.